Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

At ADA this year, type 2 drugs for type 1 diabetes show lots of promise. Plus, the latest exciting data on the Medtronic Veo and hypoglycemia.
For World Diabetes Day on November 14, Abbott released a cool new interactive infographic about A Day in the Life of an Insulin-Using Patient . Approximately 26% of the...
MannKind’s inhalable ultra-rapid-acting insulin Afrezza has its day at the FDA – find out what it can do for patients and how to speak up!
A whole new approach to treating type 2 diabetes at diagnosis, a new type of metformin, and the benefit of adding a GLP-1 agonist to insulin.
The three top trends we saw in diabetes in 2013.
The Food and Drug Administration (FDA) on March 29, 2013 announced its approval of Janssen Pharmaceuticals' Invokana (canagliflozin), a new SGLT-2 inhibitor for type 2...
On March 3, AstraZeneca announced FDA approval for the Bydureon dual-chambered pen (once-weekly exenatide) to improve glycemic control in people with type 2. The device...
We ask ACA expert Dr. Jack Lord all the hard questions on healthcare coverage and reimbursement.
We travel to Oregon to support test strip access for people with diabetes. Find out what transpired!
On March 25, Lilly and Boehringer Ingelheim (BI) announced that they submitted an application to the FDA for empagliflozin, an SGLT-2 inhibitor, for type 2 diabetes...
Cellnovo recently launched its mobile-enabled insulin pump system in the UK, after receiving very positive feedback from a usability study that began in the UK in...
On June 27, the FDA approved MannKind’s Afrezza for type 1 and type 2 diabetes, a new rapid-acting inhaled insulin. We’ve been following this story for years in diaTribe...
Twitter Summary: Novo Nordisk’s Xultophy gets positive recommendation in Europe, full approval to hopefully come soon! On July 25, Novo Nordisk announced that the...
Twitter summary: After huge anticipation for this innovative drug combination, Novo Nordisk’s Xultophy received approval in Europe for #T2D, 1 st ever basal insulin/GLP-...
On June 5, Xeris Pharmaceuticals announced that the first patient had been dosed in its phase 2 clinical trial , which is testing “mini-dose” glucagon for the treatment...
How many different factors can affect blood glucose? See the 22 things that can change your blood sugar in the short-term...
Twitter Summary: FDA approves Trulicity for #T2D, 1 st ready-to-use once-weekly GLP-1 agonist in the US, with a patient-friendly “auto-injector” – launch for later this...
On June 17, Boehringer Ingelheim (BI) and Lilly announced the resubmission to the FDA of the SGLT-2 inhibitor Jardiance (empagliflozin) for the treatment of type 2...
Twitter summary: FDA grants “tentative approval” to Lilly/BI’s Basaglar – new insulin option will be an alternative to Lantus in future On August 18, Eli Lilly and...
Twitter Summary: @LillyPad receives EU approval for Humalog 200 units/ml Kwikpen – 600 units of insulin in a 3 ml pen, hopeful US resubmission late 2014 Eli Lilly...

Pages